DEFEROXAMINE FOLLOWED BY CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN, THIOTEPA, INDUCTION REGIMEN IN ADVANCED NEUROBLASTOMA - PRELIMINARY-RESULTS

被引：70

作者：

DONFRANCESCO, A

DEBERNARDI, B

CARLI, M

MANCINI, A

NIGRO, M

DESIO, L

CASALE, F

BAGNULO, S

HELSON, L

DEB, G

机构：

[1] IST GIANNINA GASLINI, GENOA, ITALY

[2] PEDIAT CLIN, PADUA, ITALY

[3] PEDIAT CLIN, BOLOGNA, ITALY

[4] PEDIAT CLIN, NAPLES, ITALY

[5] PEDIAT CLIN, BARI, ITALY

来源：

EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷 / 04期

关键词：

DEFEROXAMINE; NEUROBLASTOMA; CYTOXAN; ETOPOSIDE; CARBOPLATIN; THIOTEPA; D-CECAT; IRON CHELATION;

D O I：

10.1016/0959-8049(95)00068-T

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Based upon phase I and II studies of deferoxamine alone and in combination with cytotoxic agents cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT), we initiated a single arm multicentre trial in 1992 for advanced neuroblastoma. 57 of 65 patients who entered the trial were evaluable. Following 4 courses of the D-CECaT, almost all the patients underwent surgery. Toxicity was moderate and mainly reversible myelosuppression. The post-surgically defined responses in stage 3 high risk, stage 4 moderate risk and stage 4 high risk patients included 24 complete responses, 26 partial responses, and 3 minor responses, and 4 patients had progressive disease. These patients are being followed to determine the impact of this programme on their overall survival.

引用

页码：612 / 615

页数：4

共 24 条

[1]

AUGUST CS, 1989, AUTOLOGOUS BONE MARR, P567

[2] REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].

BRODEUR, GM ;

PRITCHARD, J ;

BERTHOLD, F ;

CARLSEN, NLT ;

CASTEL, V ;

CASTLEBERRY, RP ;

DEBERNARDI, B ;

EVANS, AE ;

FAVROT, M ;

HEDBORG, F ;

KANEKO, M ;

KEMSHEAD, J ;

LAMPERT, F ;

LEE, REJ ;

LOOK, AT ;

PEARSON, ADJ ;

PHILIP, T ;

ROALD, B ;

SAWADA, T ;

SEEGER, RC ;

TSUCHIDA, Y ;

VOUTE, PA .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477

[3] INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].

BRODEUR, GM ;

SEEGER, RC ;

BARRETT, A ;

BERTHOLD, F ;

CASTLEBERRY, RP ;

DANGIO, G ;

DEBERNARDI, B ;

EVANS, AE ;

FAVROT, M ;

FREEMAN, AI ;

HAASE, G ;

HARTMANN, O ;

HAYES, FA ;

HELSON, L ;

KEMSHEAD, J ;

LAMPERT, F ;

NINANE, J ;

OHKAWA, H ;

PHILIP, T ;

PINKERTON, CR ;

PRITCHARD, J ;

SAWADA, T ;

SIEGEL, S ;

SMITH, EI ;

TSUCHIDA, Y ;

VOUTE, PA .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881

[4]

Carli M., 1982, PEDIATRIC ONCOLOGY, P141

[5]

CASTELLO MA, 1991, PROG CLIN BIOL RES, V366, P535

[6]

DONFRANCESCO A, 1990, CANCER RES, V50, P4929

[7] DEFEROXAMINE, CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN, AND THIOTEPA (D-CECAT) - A NEW CYTOREDUCTIVE CHELATION-CHEMOTHERAPY REGIMEN IN PATIENTS WITH ADVANCED NEUROBLASTOMA [J].

DONFRANCESCO, A ;

DEB, G ;

DOMINICI, C ;

ANGIONI, A ;

CANIGLIA, M ;

DESIO, L ;

FIDANI, P ;

AMICI, A ;

HELSON, L .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (04) :319-322

[8] MULTIAGENT CHEMOTHERAPY FOR CHILDREN WITH METASTATIC NEURO-BLASTOMA - REPORT FROM CHILDRENS CANCER STUDY-GROUP [J].

FINKLESTEIN, JZ ;

KLEMPERER, MR ;

EVANS, A ;

BERNSTEIN, I ;

LEIKIN, S ;

MCCREADIE, S ;

GROSFELD, J ;

HITTLE, R ;

WEINER, J ;

SATHER, H ;

HAMMOND, D .

MEDICAL AND PEDIATRIC ONCOLOGY, 1979, 6 (02) :179-188

[9]

FREI E, 1988, CANCER RES, V48, P6417

[10]

GAYNON P, 1989, P AN M AM SOC CLIN, V8, P306

← 1 2 3 →